Drug

MK-2225 (ACE-1334)

Status:
Phase 1
Condition:
Systemic Sclerosis ILD
Intervention Type:
Subcutaneous (SC) Injection
Funder Type:
Industry

Drug Details

MK-2225 (ACE-1334) is designed to bind and inhibit TGF-beta 1 and 3 ligands but not TGF-beta 2. 

Study Purpose

This Phase 1b/2 study is designed to assess the safety, efficacy, PK, and PD of ACE-1334 plus SOC in participants with diffuse Systemic Sclerosis (SSc) with or without ILD (Phase 1b) and SSc-ILD (Phase 2).

Find a Clinical Trial